Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 27
HOS-086006 · Präparat HOS-083234
Musculoskeletal and connective tissue disorders
Arthralgia9 Rhabdomyolysis11
Renal and urinary disorders
Urinary incontinence,
urinary retention
Urinary hesitation11
Pregnancy, puerperium and perinatal conditions
Drug
withdrawal
syndrome
neonatal
(see
section
4.6)
Reproductive system and breast disorders
Erectile dysfunction Amenorrhea Priapism12
in males Breast enlargement
Decreased libido in Galactorrhea in
males and females females
Gynaecomastia/breast
enlargement in males
General disorders and administration site conditions
Asthenia
Fatigue
Oedema
Pyrexia10
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage 9125244b4ced4b6cc5378cbde59063d6074441ddc3e72112ab5bf9f205cfcb29 · Zeichen 6941–8462 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 27–28
HOS-086007 · Präparat HOS-083234
27
Investigations
Elevated Increased alkaline Increased total
plasma phosphatase10 bilirubin
prolactin High creatine
levels8 phosphokinase11
High Gamma
Glutamyltransferase
10
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage ae24b892af6256e77b1d83c127eeb52cff557c458354b941c13eca795eed09ac · Zeichen 8513–8812 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 28
HOS-086008 · Präparat HOS-083234
High Uric acid 10
1
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI)
categories. Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline
body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon
(0.8 %). Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term
exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
2
Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were
greater in patients without evidence of lipid dysregulation at baseline.
3
Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high
(≥ 6.2 mmol/l). Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 -
< 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
4
Observed for fasting normal levels at baseline (< 5.56 mmol/l) which increased to high (≥ 7 mmol/l).
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/l) to high (≥ 7 mmol/l) were
very common.
5
Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high
(≥ 2.26 mmol/l). Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l -
< 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
6
In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was
numerically higher, but not statistically significantly different from placebo. Olanzapine-treated patients
had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses of
haloperidol. In the absence of detailed information on the pre-existing history of individual acute and
tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces
less tardive dyskinesia and/or other tardive extrapyramidal syndromes.
7
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been
reported when olanzapine is stopped abruptly.
8
In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of
normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin
value. In the majority of these patients the elevations were generally mild, and remained below two
times the upper limit of normal range.
9
Adverse event identified from clinical trials in the Olanzapine Integrated Database.
10
As assessed by measured values from clinical trials in the Olanzapine Integrated Database.
11
Adverse event identified from spontaneous post-marketing reporting with frequency determined
utilising the Olanzapine Integrated Database.
12
Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the
upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage 8dd7f83a6d904fa3e42d1fd34de6abbae53e9c9af205df8ec7b4fbffe114959f · Zeichen 8835–11798 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 28–29
HOS-086009 · Präparat HOS-083234
28
Undesirable effects listed and observed following administration of oral and LAIM olanzapine,
13
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage 63b96cb052998abfb1b17e41da620d52c8bc89c0f66a8b33ccafa1df072ee926 · Zeichen 11855–11956 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086010 · Präparat HOS-083234
which may also occur following administration of RAIM olanzapine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage fe4a73801dc7e281025914ca7daa626e745bc1ed6bd7b9fd9e3a4d5d7d7e4fe1 · Zeichen 11960–12025 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086011 · Präparat HOS-083234
Long-term exposure (at least 48 weeks)
The proportion of patients who had adverse, clinically significant changes in weight gain, glucose,
total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12
months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage b1487d5eecae90ae5345661370e6e71220396dfab91841f22ba335857762911b · Zeichen 12027–12365 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086012 · Präparat HOS-083234
Additional information on special populations
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher
incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4). Very
common adverse reactions associated with the use of olanzapine in this patient group were abnormal
gait and falls. Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and
urinary incontinence were observed commonly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage d3ff8afa7e22632a9df18c9bb93097910e8ce26cdfeb9f04479f98815a6175b4 · Zeichen 12367–12862 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086013 · Präparat HOS-083234
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with
Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported
very commonly and more frequently than with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage c29040ea7fa8697b2fb783bf69a1db1963559b0ed961ec03969ed7a0a9388588 · Zeichen 12864–13105 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086014 · Präparat HOS-083234
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine
resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma
valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels
(≥ 10%) of tremor, dry mouth, increased appetite, and weight gain. Speech disorder was also reported
commonly. During treatment with olanzapine in combination with lithium or divalproex, an increase
of ≥ 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6
weeks). Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with
bipolar disorder was associated with an increase of ≥ 7% from baseline body weight in 39.9% of
patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage 267d0de598d79ab80f468b80290e8da217253e875563438ae177bbbae129b9af · Zeichen 13107–13905 im Abschnitt
Nebenwirkungen · Zyprexa
ZYPREXA 10 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 29
HOS-086015 · Präparat HOS-083234
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system listed
in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:10:00Z · SHA-256 d7a60e6f4908c9e7d3e4f8ff39c56bf74a1014719fb7cace04436a065b4d3357 · Passage f79adadb3e7ac31ce15545a76bbcec1828bc16712af1fec9ad46e11a12f08926 · Zeichen 13907–14262 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.